Loading company
Edgewise Therapeutics, Inc.
EWTX · Nasdaq · ·
Next earnings: November 5, 2026
$39.19-1.5%Sep 29 close
- 1M
- -8.3%
- 6M
- +29.4%
- 1Y
- +141.6%
- 5Y
- +136.1%
EWTX · Nasdaq · ·
Next earnings: November 5, 2026
$39.19-1.5%Sep 29 close
Edgewise Therapeutics, Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$57.3M | -$36.1M | -58.73% |
| Profit per share | -$0.53 | -$0.34 | -55.88% |
| Free Cash Flow | -$42.5M | -$32.6M | -30.24% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Edgewise Therapeutics, Inc. has no earnings call transcript available.
“In the second quarter, Edgewise entered into a deal to sell sevasemten and our muscular dystrophy business to Servier. Our post-deal close financial position enhances our ability to advance EDG-7500 and our cardiovascular-focused pipeline toward important clinical and regulatory milestones as an independent company,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Edgewise Therapeutics is a leading biopharmaceutical company focused on novel, muscle-targeted therapeutics. Leveraging its expertise in muscle biology and small molecule drug development, Edgewise is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy, heart failure and other serious cardiovascular and cardiometabolic conditions. To learn more, go to edgewisetx.com or follow Edgewise on LinkedIn , X , Facebook and Instagram .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Edgewise Therapeutics, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.